Hematology Weekly News – September 15th 2025 Hematology Update: Jaypirca CLL win, BTK degrader data, WHO EML update and More From Phase 3 CLL PFS superiority (Jaypirca) […] The post Hematology Weekly News – September 15th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – September 15th 2025 #News #AML #Annamycin #Biosplice #CellCentric Comment below!

Moleculin Biotech Engages Investors at Virtual 'Top 5 for '25' Conference Moleculin Biotech, a pharmaceutical firm, presents key insights at the Virtual Investor Conference, highlighting investment potential in 2025.

Moleculin Biotech Engages Investors at Virtual 'Top 5 for '25' Conference #United_States #Houston #Moleculin_Biotech #Annamycin #MBRX

Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment Moleculin Biotech has secured additional patent allowances for Annamycin, aiming to enhance its global exclusivity and expedite clinical trials for cancer therapies.

Moleculin Biotech Strengthens Global Patent Portfolio for Annamycin, Aiming for Next-Gen Cancer Treatment #USA #Houston #Moleculin_Biotech #Annamycin #Phase_3_Trial

Moleculin Biotech’s Abstract Gains Acceptance for Presentation at International Leukemia Symposium Moleculin Biotech's breakthroughResearch on acute myeloid leukemia will be showcased in a poster presentation at the ISALXIX symposium.

Moleculin Biotech’s Abstract Gains Acceptance for Presentation at International Leukemia Symposium #United_States #Houston #AML #Moleculin_Biotech #Annamycin

Moleculin Biotech Secures $5.8 Million Through Warrant Exercise Moleculin Biotech, a late-stage pharmaceutical firm, announces the exercise of warrants generating $5.8 million to advance its cancer treatments.

Moleculin Biotech Secures $5.8 Million Through Warrant Exercise #United_States #Houston #Annamycin #Moleculin #MBRX

Moleculin Biotech Makes Progress with FDA on Key AML Clinical Trial Approval Moleculin Biotech receives positive FDA guidance for the MIRACLE trial, accelerating the development timeline for AML treatment. This pivotal trial aims to treat hard-to-treat tumors effectively.

Moleculin Biotech Makes Progress with FDA on Key AML Clinical Trial Approval #USA #Houston #Moleculin_Biotech #Annamycin #AML_Treatment

Moleculin's Groundbreaking Approval Marks Start of Phase 3 AML Clinical Trials in Europe Moleculin Biotech receives first regulatory approval in Europe to recruit participants for its pivotal Phase 3 trial aimed at treating relapsed acute myeloid leukemia.

Moleculin's Groundbreaking Approval Marks Start of Phase 3 AML Clinical Trials in Europe #United_States #Houston #AML #Annamycin #Moleculin

Moleculin Biotech Shares Updates on AML Trial Progress in Virtual Investor Segment Moleculin Biotech participates in a virtual investor segment highlighting advancements in its pivotal AML trial, emphasizing the Annamycin treatment strategy.

Moleculin Biotech Shares Updates on AML Trial Progress in Virtual Investor Segment #USA #Houston #Moleculin_Biotech #Annamycin #AML_Trial